Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.4K
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

968
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
968
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.1K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.1K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

492
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
492
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

864
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
864
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

554
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
554

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Triggering of viral and bacterial respiratory infection hospitalizations by traffic pollution exposure in a cohort of hospitalized adults.

PloS one·2026
Same author

Early-life gut microbiome composition and rotavirus vaccine-induced IgA responses in U.S. infants: a longitudinal cohort study.

EBioMedicine·2026
Same author

Discriminating Bacterial from Nonbacterial Lower Respiratory Tract Infection within Clinical Subgroups of Hospitalized Adults.

The Journal of infectious diseases·2026
Same author

PXN Unlocks the Power of Public Gene Expression Data Through Cross-Technology Integration.

bioRxiv : the preprint server for biology·2026
Same author

Translating the ABCSs into HIV Care: A Stepped Wedge Cluster Randomized Clinical Trial.

Journal of general internal medicine·2026
Same author

A place for common ground: the history of the National Institute of Health and Research in the United States.

Pediatric research·2026

関連する実験動画

Updated: Jan 28, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.5K

乳児における急性疾患重症度および再発性喘鳴の予測因子としての鼻内バイオマーカー:RSウイルス(RSV)感染症

Mary T Caserta1, Thomas J Mariani1, Edward E Walsh2

  • 1Department of Pediatrics1, University of Rochester Medical Center, Rochester, NY  USA.

The Journal of infectious diseases
|January 27, 2026
PubMed
まとめ

乳児のRSウイルス(RSV)感染症は再発性喘鳴と関連している。RSV感染中の鼻内遺伝子発現は、乳児における将来の再発性喘鳴を予測することができる。

キーワード:
RSV差次的発現遺伝子(DEG)遺伝子発現プロファイルiGRSSメタゲノムマイクロバイオーム再発性喘鳴

さらに関連する動画

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.3K
Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus
09:08

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

Published on: July 27, 2021

4.1K

関連する実験動画

Last Updated: Jan 28, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.5K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.3K
Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus
09:08

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

Published on: July 27, 2021

4.1K

科学分野:

  • 小児感染症
  • 呼吸器内科学
  • マイクロバイオーム研究
  • 免疫学

背景:

  • RSウイルス(RSV)は乳児の入院の主な原因です。
  • RSV疾患を有する乳児は、再発性喘鳴を発症する可能性が高くなります。
  • RSVの重症度および長期的な呼吸器転帰に影響を与える要因を理解することは極めて重要です。

研究 の 目的:

  • 急性RSV感染中の鼻腔内遺伝子発現およびマイクロバイオーム組成と疾患重症度との関連を調査すること。
  • これらの所見と再発性喘鳴の発症との関連を調べること。
  • RSV感染後の乳児における再発性喘鳴を予測するための潜在的なバイオマーカーを特定すること。

主な方法:

  • 確認されたRSV感染を有する、以前は健康であった乳児のコホート前向き登録(2019-2023年)。
  • メタゲノムおよびトランスクリプトームシーケンシングのための鼻スワブおよび洗浄液の採取。
  • 改善されたグローバル呼吸器重症度スコア(iGRSS)を用いた疾患重症度の評価および再発性喘鳴の1年間追跡調査。
  • 遺伝子発現およびマイクロバイオームデータの解析のための多変量回帰モデルの適用。

主要な成果:

  • 405個の遺伝子が疾患重症度と有意に関連しており、特に自然免疫およびインターロイキンシグナル伝達経路のものが含まれていました。鼻内マイクロバイオーム組成は重症度と関連を示しました:DolosigranulumはiGRSSと逆相関し、Haemophilusは直接相関しました。急性RSV感染中の鼻内遺伝子発現は、マイクロバイオームデータを上回る精度で再発性喘鳴を予測しました(交差検証済みAUC=0.882)。

結論:

  • 原発性RSV感染中の鼻内遺伝子発現およびマイクロバイオームプロファイルは、急性疾患重症度および再発性喘鳴と関連しています。
  • RSV感染中の鼻腔内の宿主転写シグネチャは、その後の再発性喘鳴の予測マーカーとして機能します。
  • 本研究は、RSV感染後の乳児における長期的な呼吸器転帰の予測ツールとしての宿主遺伝子発現の可能性を強調しています。